Thulium Nanoparticles Revolutionize Cancer Radiotherapy

Researchers have developed a cutting-edge nanoplatform using thulium, a rare earth element, to transform cancer treatment through advanced radiotherapy and radiodynamic therapy. This innovation centers on dendritic mesoporous thulium oxide (DMTm) nanoparticles encapsulated with cerium clusters and a photosensitizer, then cloaked in natural killer cell-derived extracellular vesicles (NKEV). Published in early 2026, the study demonstrates how these nanoparticles address key limitations in traditional radiotherapy, such as tumor hypoxia and insufficient radiation sensitivity.

Thulium's unique properties make it ideal for this application. With its high atomic number (Z=69) and K-edge energy at 59.4 keV-perfectly matching the bremsstrahlung peak of clinical X-ray sources-thulium nanoparticles significantly boost photoelectric absorption. This leads to enhanced production of hydroxyl radicals (•OH) under X-ray irradiation, amplifying radiotherapy effects. Simultaneously, the cerium clusters act as catalase mimics, converting tumor-abundant hydrogen peroxide (H2O2) into oxygen, which alleviates hypoxia and improves treatment efficacy.

The system's brilliance lies in its multifaceted design. The photosensitizer coordination enables radiodynamic therapy by producing singlet oxygen (^1O2) through energy transfer from X-rays. NKEV coating enhances tumor targeting via NK cell receptors like NKG2D and DNAM-1, ensuring precise delivery and higher cellular uptake. In tests with MDA-MB-231 breast cancer cells, the nanoparticles achieved superior tumor cell killing at low X-ray doses (2 Gy), inducing lipid peroxidation, mitochondrial dysfunction, and DNA damage without notable toxicity to healthy cells.

This thulium-driven approach promises to reduce radiation doses, minimizing side effects for patients. In vivo studies showed marked tumor suppression, highlighting its clinical potential. As rare earth elements like thulium gain prominence in nanomedicine, this research underscores their role in precision oncology, potentially reshaping radiation therapy protocols worldwide. With thulium's scarcity driving supply chain interest, such medical breakthroughs add urgency to sustainable sourcing efforts.